Regulatory FAQ
Is BPC-157 Legal in the United States? A 2026 Regulatory Guide
The short answer: BPC-157 is not FDA-approved as a drug and is currently restricted from 503A compounding in the U.S. pending FDA review. It is not a scheduled controlled substance, but that does not make it legal for human use — the restriction sits in a different part of federal drug law. The July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting is the next scheduled review that could change compounding eligibility. This page walks through what the current status actually means, what the July 2026 review can and cannot do, and how kindr Health handles BPC-157 prescriptions today.
Current status (mid-2026)
BPC-157 (Body Protection Compound-157) has never been an FDA-approved drug. It is a 15-amino-acid synthetic peptide derived from a protective protein found in gastric juice, first characterized in the early 1990s. It has been the subject of extensive preclinical research — largely in rodent models — for tendon, ligament, gut, and vascular healing. Human clinical trial data remain limited.
In 2023, the FDA included BPC-157 on its Category 2 "do not compound" interim list — meaning licensed 503A compounding pharmacies cannot legally prepare it for patient prescriptions while the substance is under review. That status remains in effect today. Any U.S. pharmacy that continues to compound BPC-157 is doing so outside current FDA guidance and is exposing itself to enforcement action.
Why the FDA placed BPC-157 in Category 2
The FDA's stated concerns cluster in three areas: identity and characterization (BPC-157 is a synthetic peptide with no established USP monograph or reference standard), lack of human safety data at the doses being marketed, and inconsistent purity from bulk suppliers. Category 2 is explicitly an interim designation — it is not a final ruling that BPC-157 is unsafe. It is a procedural hold while the agency completes its evaluation.
What the July 2026 FDA meeting could change
The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review BPC-157, CJC-1295/ipamorelin, and other peptides in July 2026. If the committee recommends moving BPC-157 off the do-not-compound list and the FDA accepts, U.S. 503A pharmacies could legally prepare it under a physician's prescription. If the committee recommends maintaining or expanding the restriction, the current status would persist. Read our full briefing on the July 2026 review →
Historical precedent is mixed. Sermorelin was previously restricted and later returned to compoundable status when the FDA determined its safety profile and clinical use warranted it. Other peptides, including some early GHRH analogs, remained restricted. The committee weighs preclinical evidence, published human data, historical compounding use, and adverse-event reporting.
What "legal under compounding" would actually mean
A compounded medication is prepared by a licensed 503A pharmacy for an individual patient, based on a physician's prescription. It is not the same as an FDA-approved drug — compounded medications are not reviewed by the FDA for safety, efficacy, or manufacturing consistency at the finished-product level. They are a recognized regulatory pathway used widely for hormone therapy, weight-loss medications, and other formulations that are unavailable or unsuitable in commercial products.
If BPC-157 moved off Category 2, it would become a physician-prescription substance prepared by a licensed pharmacy for a specific patient. It would not become an over-the-counter product, and it would not become an FDA-approved drug. Marketing claims that describe compounded BPC-157 as "FDA-approved" would remain a regulatory misstatement even after any status change.
What research says about BPC-157 today
Preclinical evidence — largely in rat and mouse models — is consistent for tendon healing, ligament healing, muscle regeneration, and gastric ulcer repair. The mechanistic story involves promotion of angiogenesis, upregulation of growth factors including VEGF, and support of nitric-oxide-mediated healing pathways. Human data are limited to small case series and non-controlled observations. There are no large randomized controlled trials in humans to date, which is one of the reasons the FDA has held on compounding eligibility.
This does not mean BPC-157 does not work. It means the human safety and efficacy database is thin, and the FDA's regulatory posture is calibrated to that reality.
How kindr Health handles BPC-157 today
We do not prescribe BPC-157 while it remains on the do-not-compound list. This is not a marketing decision — it is a compliance decision. Any prescriber or pharmacy that continues to fill BPC-157 prescriptions under current federal rules is exposing patients to unregulated preparations and exposing themselves to enforcement action.
We provide physician-supervised education and evaluation. If the regulatory status changes after the July 2026 review, we will re-evaluate BPC-157 for our formulary based on the updated FDA guidance, the accompanying compounding standards, and each patient's individual clinical picture. In the interim, we support tissue-repair goals with evidence-based and legal alternatives, including HRT (where indicated), physical rehabilitation, nutritional support, and — for the growth-hormone axis — sermorelin, which remains compoundable. Read the full BPC-157 clinical guide →
How to think about "buying BPC-157" today
If you see BPC-157 advertised for sale online, one of three things is true. The seller is (a) marketing a research chemical for a use that is not legal, (b) operating outside FDA compounding rules, or (c) misrepresenting the product's regulatory status. None of these scenarios protect the patient. Independent third-party testing of research-grade BPC-157 has repeatedly found under-labeled peptide content, contaminants, and inconsistent purity between lots.
Bottom line
BPC-157 is not FDA-approved, is not DEA-scheduled, and is currently on the FDA Category 2 do-not-compound list. It cannot be legally compounded by a U.S. 503A pharmacy under a physician's prescription today. That may change after the July 2026 PCAC review, at which point kindr will re-evaluate. Until then, sourcing BPC-157 for personal use from research-chemical channels is neither legal nor safe. If tissue repair, tendon injury, or gut inflammation is the underlying question, there are physician-directed options available today — and the right first step is an evaluation, not a purchase.
FDA peptide review July 2026 →
What compounded peptides actually are →
Are peptides safe? →
BPC-157 full clinical guide →
Frequently asked questions
Is BPC-157 a controlled substance under DEA schedules?
No. BPC-157 is not scheduled under the Controlled Substances Act. Its restriction comes entirely from FDA compounding policy under section 503A of the Federal Food, Drug, and Cosmetic Act — not from the DEA. That means the legal barrier is at the pharmacy-preparation level, not at possession, but human use of a non-approved, non-compoundable substance is still not permitted under U.S. drug law.
Can I buy BPC-157 online?
Products labeled "for research use only, not for human consumption" are widely sold online. These are not evaluated by the FDA for identity, purity, potency, sterility, or safety. Importing them for personal human use is not legal in the U.S., and the products themselves frequently fail independent third-party testing for the claimed peptide identity and purity. kindr Health does not endorse research-chemical sourcing under any circumstances.
Would compoundable status mean BPC-157 is FDA-approved?
No. These are two entirely different regulatory pathways. Compounding eligibility (503A) allows licensed pharmacies to prepare a substance for an individual patient under a physician's prescription. FDA approval is a drug-product-level designation that requires a specific manufacturer to submit clinical safety and efficacy data through a New Drug Application (NDA). BPC-157 has never been the subject of an NDA and is unlikely to be, given its off-patent chemistry.
What happened at the FDA in 2023–2024 that changed BPC-157's status?
In 2023, the FDA formally reviewed several peptide nominations for inclusion on the 503A bulk drug substances list. BPC-157 was placed on the Category 2 "do not compound" interim list, meaning 503A pharmacies could not legally prepare it while the substance was under review. Similar Category 2 designations were applied to CJC-1295, ipamorelin, sermorelin (later removed), thymosin alpha-1, and several other peptides.
What could actually change in July 2026?
The PCAC will review evidence and vote on recommendations for whether BPC-157 and other peptides should be added to, or removed from, the 503A bulk drug substances list. Their recommendations are advisory to the FDA — the agency ultimately decides. Outcomes could include (a) moving BPC-157 off Category 2 and onto the approved compoundable list, (b) keeping it in Category 2 pending further study, or (c) declining to add it to the compoundable list at all.
Is BPC-157 legal in other countries?
Regulatory status varies. Some jurisdictions treat BPC-157 as a research chemical only; others permit prescription use under specific frameworks. This page addresses U.S. federal regulation only. Traveling with BPC-157 or importing it across borders carries additional legal exposure that is beyond the scope of pharmacy-level compounding rules.
What are the safe, legal alternatives while BPC-157 is restricted?
For tendon, ligament, and connective-tissue support, the mainstays remain: progressive loading rehabilitation, adequate protein and collagen intake, vitamin C and copper cofactors for collagen synthesis, and — where clinically appropriate — physician-supervised HRT (estrogen supports tendon and ligament matrix). GLP-1 therapy and growth-hormone-axis peptides like sermorelin remain compoundable and address adjacent goals.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-06-22. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.